BloodSTOP® and BloodSTOP® iX are biocompatible, non-irritating, woven matrices of fibers made from natural plant compounds. They adhere to a wound, initiate blood coagulation, stop bleeding, and form a protective layer to create an optimal environment for wound healing. Their water solubility allows for removal by rinsing, without disruption of a clotted surface.
These products are covered by U.S. Patent No. 7,262,181.
Vicky Feng, Chief Executive Officer and President
Vicky Feng founded LifeScience PLUS with a vision for next-generation medical products that aid medical professionals in administering care while improving patient recovery. She brings 16 years of computer industry and 12 years of medical industry entrepreneurial and management experience to the Company, guiding startups and maturing them into fully profitable enterprises. One of her earliest ventures was in the PC industry where she was on the founding team and grew the company to $10 million in annual revenues in 3 years. Ms. Feng holds a B.S. degree in Electrical Engineering from Beijing Union University.
Juan N. Walterspiel, MD, FAAP, Chief Scientific and Medical Officer
Dr. Walterspiel has over 21 years of experience in the Biotech and Pharmaceutical industries. He has served as the International Clinical Leader at Hoffman La Roche/Genentech, International Medical Director at Pfizer and Chief of Medical Affairs and Regulatory at Inhibitex. Dr. Walterspiel's contributions while Chief Medical Officer for GeneOhm led to the company’s acquisition by Becton Dickinson. Since serving in these positions, he has been a clinical development consultant for many large pharmaceutical companies and numerous startup companies.
In addition to his experience in industry, Dr. Walterspiel was an attending and teaching physician for 25 years, and still maintains Board Certification in Pediatrics. His academic career includes successive faculty positions at the University of Texas Medical School in Houston, TX and Yale Medical School in New Haven, CT. Dr. Walterspiel has authored over 40 publications and several book chapters. His research interests are broad and range from infections to sepsis (inflammatory response syndrome) to coagulation. He is a member of the IDSA, ASM, AAP, PIDS and ACRP and has served(s) on several professional committees.
Audrey Vitale, Director of Regulatory Affairs
Ms. Vitale has 14 years of experience in medical device regulation, including product approvals in the US and EU, and quality system compliance with ISO 9001, ISO 13485, EU Medical Device Directive, and FDA Quality System Regulation. Ms. Vitale jointed LifeScience PLUS after 9 years as Regulatory Affairs Director for Ultracell Medical Technologies, an ophthalmology and ENT device manufacturer, where she was responsible for regulatory affiars, quality assurance, product and manufacturing validation, and quality system development and compliance. Prior to working in the medical device field, Ms. Vitale was a process engineer for Corning, Inc. in their optical fiber manufacturing division. Ms. Vitale has a B.S. in Materials Engineering from Rensselaer Polytechnic Institute, and is a member of the Regulatory Affairs Professional Society, with certification in US Regulatory Affairs.
Patrick Lin, Business Advisor
Patrick Lin has over 18 years of senior-level experience in US and China related investment management and equity capital markets, conducting over 1,500 public company management meetings and leading or co-managing over 250 equity capital offerings. Since 2002 he has been Portfolio Manager and Chief Investment Officer of Primarius Capital, an investment firm with holdings in technology, healthcare, consumer, and China-related sectors. Primarius has been one of the earliest investors in SINA Corp (leading Internet and Weibo company in China) and Questcor (emerging pharmaceutical company). While at Primarius he has been responsible for all aspects of the company's growth and operations, and launched one of the earliest China-focused hedge funds in the US. Mr. Lin was a co-founding partner of E*Offering, the investment bank of E*Trade, serving as Managing Director, Equity Capital Markets, and Executive Committee member. E*Offering was involved in over 100 public offerings in its first 15 months of operations (1 out of 2 internet IPOs) and was acquired by Wit Capital for $328M in 2000. Prior to E*Offering, Mr. Lin was a Principal in Institutional Research Sales at Robertson Stephens & Co., playing a significant role in many of the firm's successful IPOs of multi-billion dollar market cap companies, and developing the firm's MBA recruiting program during a period of rapid company growth. Mr. Lin holds an MBA from Kellogg Graduate School of Management and a Bachelor of Science in Business Administration from the University of Southern California.
Board of Directors
Vicky Feng, Chairman
Vicky Feng founded LifeScience PLUS with a vision for next-generation medical products that aid medical professionals in administering care while improving patient recovery. Serving as Chief Executive Officer and President, she brings 12 years of medical and 16 years of computer industry entrepreneurial and management experience to the Company, guiding startups and maturing them into fully profitable enterprises. One of her earliest ventures was in the PC industry where she was on the founding team and grew the company to $10 million in annual revenues in 3 years. Ms. Feng holds a B.S. degree in Electrical Engineering from Beijing United University.
David Young, Pharm.D., Ph.D.
Dr. Young joined the LSP Board of Directors in June of 2012. He is currently the CSO of Questcor Pharmaceuticals, a position he's held since October 2009. Prior to that, Dr. Young served as Executive Director & President, U.S. Operations of AGI Therapeutics plc since 2006. Previous to 2006, Dr. Young was the Executive Vice President of the Strategic Drug Development Division of ICON plc, an international CRO, and founder and CEO of GloboMax LLC, a contract drug development firm purchased by ICON plc in 2003. Prior to forming GloboMax, Dr. Young was an Associate Professor at the School of Pharmacy, University of Maryland-VA Clinical Research Unit. Dr. Young has represented more than 30 sponsors at the Food and Drug Administration (FDA), worked on more than 70 drug products, and been involved with more than 30 NDA submissions. Dr. Young has an extensive background in drug development that includes more than 150 presentations and authored publications, including formal presentations to the FDA and numerous invited presentations at scientific meetings. Dr. Young is an expert in 505(b)(2) drug development, having worked on more than 25 programs in various therapeutic areas including Central Nervous System diseases and disorders.
Dr. Kenneth Robinson, DMD MS
Dr. Robinson taught oral and maxillofacial surgery at Tufts University before beginning his private practice. He has been in private practice for thirty three years. He has been honored as a Board Diplomat, American Board of Oral Surgery; Fellow, American Dental Society of Anesthesiology; Fellow, American Association of Oral and Maxillofacial Surgeons and a Diplomat of the National Dental Board of Anesthesiology. Dr. Robinson has authored publications in scientific journals. He holds a DMD degree from the University of Pennsylvania and a MS in pharmacology from the University of Rochester.
James Little, Esquire
James Little has forty-five years of experience practicing corporate law during which time he has represented private business concerns throughout Silicon Valley. He has focused his firm’s practice on the formation and legal representation of growth companies. Mr. Little is a graduate of Harvard College and Stanford Law School.